enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

3. Monomethyl auristatin E - Wikipedia

   en.wikipedia.org/wiki/Monomethyl_auristatin_E

   Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.

4. Tisotumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Tisotumab_vedotin

   Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .

5. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

7. Depatuxizumab mafodotin - Wikipedia

   en.wikipedia.org/wiki/Depatuxizumab_mafodotin

   148 251.25 g·mol −1 Depatuxizumab mafodotin ( INN ; development code ABT-414 ) is an antibody-drug conjugate designed for the treatment of cancer. [ 1 ] [ 2 ] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.

8. Emibetuzumab - Wikipedia

   en.wikipedia.org/wiki/Emibetuzumab

   Emibetuzumab (INN [1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. [2] It is in phase II trials for patients with NSCLC [3] This drug was developed by Eli Lilly & Company.

9. Mapatumumab - Wikipedia

   en.wikipedia.org/wiki/Mapatumumab

   A phase 1 clinical trial in 2004 demonstrated the safety and tolerability of mapatumumab in cancer patients with advanced solid tumors or non-Hodgkin’s lymphoma, and supported further evaluation in phase 2 clinical trials, both as a single agent and in combination with chemotherapy. [4]